Trial Profile
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Melphalan (Primary) ; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Filgrastim; Mesna; Topotecan; Vincristine
- Indications Neuroblastoma
- Focus Adverse reactions; Pharmacogenomic
- 05 Apr 2023 This study protocol has been amended as the phase of the study has been changed to Phase 1
- 01 Jun 2021 Results published in the Transplantation and Cellular Therapy
- 11 Oct 2019 Status changed from suspended to active, no longer recruiting.